Clinical activity across multiple hard to treat traditionally immune-unresponsive tumor types as a single agent. Confirms abscopal effect across multiple tumor types. Improved antigen presentation in the tumor microenvironment. Further confirms mechanism of action and rationale for use with CPI's.
Stable disease with low toxicity is the new goal in these difficult to treat tumor types. Safety profile remains stellar. Adds to and supports everything that has been postulated thus far. Predicts likely very good results when a CPI is added. No treatment options available for most of these refractory stage IV patients. No earth shattering headlines here, but further foundation building for expansion into multiple solid tumors ( huge market) and approval. Likelihood that pairing with many CPI's and/or other immunologic agents is possible based on safety and predictable enhancement of the microenvironment. All good. Keep building.